GHK-Cu vs Tesamorelin
Well Studied vs FDA Approved
synergistic Mechanism-based · 47% GHK-Cu and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
GHK-Cu Tesamorelin
Weight 404.96 Da 5,135.9 Da
Half-life 0.5-2 hours 26-38 minutes
Chain 3 amino acids 44 amino acids
Type Copper tripeptide GHRH analog
Key Benefits
GHK-Cu
01 Enhanced collagen production (70% increase in type I and III)
02 Improved skin elasticity
03 Reduced fine lines and wrinkles
04 Accelerated wound healing
05 Hair growth stimulation
06 Antioxidant protection
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
GHK-Cu
0.5-2% topical or 1-3mg injectable / 1-2x daily
Systemic anti-aging 1-2mg 1x daily
Enhanced regeneration 2-3mg 1-2x daily
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
GHK-Cu
Mild skin irritation initially (usually resolves)
Increased photosensitivity
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Known copper sensitivity or Wilson's disease
Active skin infections at application site
Pregnancy or breastfeeding (injectable)
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
GHK-Cu Tesamorelin
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest July 2025 June 2025
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.